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ABSTRACT
Background. Observational studies relying on clinically obtained data have shown that acute kidney injury (AKI) is linked to
accelerated chronic kidney disease (CKD) progression. However, prior reports lacked uniform collection of important
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confounders such as proteinuria and pre-AKI kidney function trajectory, and may be susceptible to ascertainment bias, as
patients may be more likely to undergo kidney function testing after AKI.
Methods. We studied 444 adults with CKD who participated in the prospective Chronic Renal Insufficiency Cohort (CRIC)
Study and were concurrent members of a large integrated healthcare delivery system. We estimated glomerular filtration
rate (eGFR) trajectories using serum creatinine measurements from (i) the CRIC research protocol (yearly) and (ii) routine
clinical care. We used linear mixed effects models to evaluate the associations of AKI with acute absolute change in eGFR
and post-AKI eGFR slope, and explored whether these varied by source of creatinine results. Models were adjusted for
demographic characteristics, diabetes status and albuminuria.
Results. During median follow-up of 8.5 years, mean rate of eGFR loss was 0.31 mL/min/1.73 m2/year overall, and 73
individuals experienced AKI (55% Stage 1). A significant interaction existed between AKI and source of serum creatinine for
acute absolute change in eGFR level after discharge; in contrast, AKI was independently associated with a faster rate of
eGFR decline (mean additional loss of 0.67 mL/min/1.73 m2/year), which was not impacted by source of serum creatinine.
Conclusions. AKI is independently associated with subsequent steeper eGFR decline regardless of the serum creatinine
source used, but the strength of association is smaller than observed in prior studies after taking into account key
confounders such as pre-AKI eGFR slope and albuminuria.
Keywords: acute kidney injury, chronic kidney disease, epidemiology, risk factor
INTRODUCTION
Acute kidney injury (AKI) is an important public health issue
that affects up to one in five hospitalizations in the USA [1–6].
While historically an episode of AKI has often been considered
a self-limited process followed by recovery of kidney function
among survivors, this notion has been challenged by an increas-
ing number of studies demonstrating the interconnected, bidirec-
tional relationship between AKI and chronic kidney disease
(CKD) [7–12]. In recent years, observational studies have reported
that AKI is closely associated with higher risk of subsequent de-
cline in kidney function, including development of incident CKD
and accelerated progression of pre-existing CKD [7–15].
Nevertheless, questions have arisen about the validity of
these associations due to the fact that almost all previous obser-
vational studies have relied on the use of clinical databases [16,
17]. A potential source of biased estimates from prior studies
may be residual confounding by important, but uncaptured
shared risk factors for AKI and CKD progression. Particularly im-
portant may be degree of proteinuria and rate of kidney func-
tion decline before an AKI episode. Few published studies on
the impact of AKI on subsequent kidney function trajectory
have accounted for potential confounding by proteinuria and
preceding estimated glomerular filtration rate (eGFR) slope.
Proteinuria may be a particularly important confounder since it
has been shown to be a strong risk factor both for development
of AKI [8, 18] and for more rapid loss of kidney function [19, 20].
Some have also hypothesized that any more rapid loss of eGFR
observed after an episode of AKI mostly reflects more rapid loss
of eGFR already present before AKI [21]. Ascertainment bias
may also overestimate the strength of association between AKI
and subsequent kidney function decline, as patients who sur-
vived AKI may get more frequent laboratory monitoring [16, 21].
We addressed these challenges by examining a group of
adults with CKD who were both participants in the prospective
Chronic Renal Insufficiency Cohort (CRIC) Study [22, 23] and
concurrent members of an integrated healthcare delivery sys-
tem with comprehensive electronic health records. The CRIC
Study provided us with protocol-driven kidney function meas-
urements and uniform ascertainment of key confounders such
as proteinuria and eGFR slope before AKI, while data from the
integrated healthcare delivery system allowed for comprehensive
capture of AKI episodes. Pairing of research protocol-driven se-
rum creatinine (SCr) measurements with clinical SCr measure-
ments in the same patients gave us a unique opportunity to
explore if any observed associations of AKI with subsequent tra-
jectories of kidney function decline varied by the source of kidney
function measurements.
MATERIALS ANDMETHODS
Study population
We identified the subset of 444 CRIC participants who were con-
current members of Kaiser Permanente Northern California.
The CRIC Study is a prospective, multi-center observational co-
hort study that initially enrolled 3939 adult participants with CKD
between 2003 and 2008. The study design, methods and baseline
characteristics of CRIC participants have been previously pub-
lished [22–24]. Adults aged 21–74 years who had an eGFR between
20 and 70 mL/min/1.73 m2 were recruited from seven clinical
centers (13 recruitment sites) in the US. CRIC participants had
baseline and annual SCr measurements that were calibrated to
isotope dilution mass spectrometry-traceable standards within a
central research laboratory at the University of Pennsylvania.
Kaiser Permanente Northern California is a large integrated
healthcare delivery system currently caring for >4.3 million
members throughout the San Francisco and greater Bay area.
Essentially all care provided is captured through a comprehen-
sive electronic health record system, including hospitalizations
and laboratory data from ambulatory/inpatient settings. Less
than 10% of hospitalizations for Kaiser Permanente members
occur outside of Kaiser Permanente hospitals and even in those
cases, for financial reasons, patients are frequently repatriated
back to Kaiser Permanente-owned facilities to complete inpa-
tient stays, so the extent of missing data is small.
The parent CRIC Study and this ancillary study were approved
by the institutional review boards of Kaiser Permanente Northern
California and the University of California, San Francisco.
Identification of AKI
The primary predictor was the occurrence of AKI detected
within a Kaiser Permanente Northern California hospital from
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enrollment in CRIC through 13 January 2015. We defined AKI as
a 50% relative increase from the nadir to peak inpatient SCr
concentration within a hospitalization during our study period.
This more stringent definition was adapted from contemporary
consensus AKI definitions [25, 26] to increase the likelihood of a
true AKI episode, as the inclusion of small absolute changes in
SCr (i.e. by 0.3 mg/dL only) may misclassify patients, especially
at higher baseline SCr values [27]. The peak inpatient SCr may
follow or precede the nadir inpatient creatinine as we were in-
terested in capturing both community-acquired and hospital-
associated/hospital-acquired cases of AKI. We deliberately
chose not to use outpatient SCr as baseline to determine
whether AKI occurred in order to avoid using outpatient SCr to
define both the exposure and the outcome, which may lead to
undesirable coupling in the analysis. Instead, we felt it was
cleaner to define the exposure—AKI—using only inpatient SCr
values, and define the outcome—outpatient eGFR trajectory—
using only outpatient SCr values. Urine output criteria were not
incorporated due to lack of systematically available data [28].
Severity of AKI was based on relative change in SCr in accor-
dance with the Kidney Disease: Improving Global Outcomes
(KDIGO) stages [25] (with all dialysis-treated AKI categorized as
Stage 3). We used the first episode of inpatient AKI observed
during the study period for any participant.
Period of observation and measurements of outcome
Participants were followed from the date of CRIC enrollment
until death, development of ESRD (defined as receipt of mainte-
nance dialysis or kidney transplant) or the date of last available
CRIC research SCr measurement through 13 January 2015 or end
of health plan membership. The main outcome of interest was
trajectory of kidney function modeled using outpatient eGFR
values before and after an episode of AKI. We calculated eGFR
using the Chronic Kidney Disease Epidemiology Collaboration
creatinine equation [29] on the basis of age, sex, race and SCr.
Two sources of outpatient SCr data were available for each pa-
tient to calculate eGFR: (i) measurements performed annually
as part of the CRIC research protocol and (ii) measurements per-
formed in the outpatient, non-emergency department setting
as part of routine clinical care at Kaiser Permanente Northern
California.
Again, inpatient measurements of SCr from Kaiser
Permanente Northern California were only used to ascertain
AKI status (primary exposure) but not for the outcome of inter-
est (trajectory of outpatient kidney function). SCr measure-
ments in Kaiser Permanente Northern California have also been
calibrated to isotope-dilution mass spectrometry-traceable
standards [30, 31].
Covariates
Age, sex, self-reported race, diabetes status and degree of albu-
minuria were defined using baseline CRIC visit data [22–24]. For
this analysis, race categories were black versus nonblack. Diabetes
was defined as self-reported use of diabetes medications or having
a fasting glucose 126 mg/dL or nonfasting glucose 200 mg/dL
[23, 32]. Four categories of albuminuria were defined using urine
albumin-to-creatinine ratios (ACR) obtained at entry to CRIC:
ACR<30 mg/g (reference); 30 mg/gACR 299 mg/g; 300 mg/
gACR  999 mg/g; and ACR1000 mg/g [22, 23].
Statistical analysis
We used linear mixed effects models to determine the associa-
tion between an episode of AKI and (i) subsequent absolute
change in outpatient eGFR and (ii) subsequent rate of eGFR de-
cline (i.e. change in eGFR slope). Both clinical and research out-
patient eGFRs were entered in the model, with the primary
predictor being time-updated AKI. Covariates in the model in-
clude: age, sex, race, baseline albuminuria category, diabetes
status, source of SCr (clinical versus research), an interaction
term for AKI and source of SCr, time since enrollment in CRIC
(to describe the eGFR decline over time) and time elapsed since
AKI among those with an AKI episode during the study period
(to describe the change in eGFR decline over time after an AKI
episode). This model estimates the rate of eGFR as a linear func-
tion over time, taking into account the varying number and
spacing of measurements of eGFR from the two sources (clinical
versus research) as well as the variable follow-up time for each
subject. A major advantage of using mixed effects modeling is
that it takes into account all of the outpatient eGFR readings for
a given person (versus a strategy of only comparing a single pre-
hospitalization eGFR used as the referent to a single post-
hospitalization eGFR). This approach also reduced the effect of
noise due to random measurement error in any given outpa-
tient eGFR reading and handles well variations in number of
eGFR readings and spacing between them. We hypothesized
that an episode of AKI would be associated with both an abso-
lute decrease in outpatient eGFR level as well as a subsequently
steeper (i.e. more negative) slope in eGFR.
We next explored whether the strengths of these associa-
tions may vary depending on the source of SCr used to calculate
eGFR. Testing the interaction between source of SCr and AKI
allowed us to determine if the absolute change in the next avail-
able outpatient eGFR measurement post-AKI differed according
to the source of SCr measurement. Testing the interaction be-
tween source of SCr and time elapsed after AKI allowed us to
determine if eGFR trajectory (i.e. slope) differed according to the
source of SCr measurement. Supplementary data, Figure S1 con-
ceptualizes the linear mixed effects model with the interactions
tested. Analyses were performed using SAS, v9.3 (Cary, NC,
USA).
RESULTS
Among 444 eligible patients, mean age at CRIC enrollment was
60.3 years; 67% were women; 34% were black; and mean base-
line eGFR was 51.0 mL/min/1.73 m2 (Table 1). Nearly 40% of
patients had a baseline urine ACR 30 mg/g, and >30% had dia-
betes at study entry. Median observation period was 8.5 years
[interquartile range (IQR) 4.5–9.8 years]. Seventy-three partici-
pants (16% of cohort) experienced at least one episode of AKI,
with 45% being Stage 2 or worse (Table 1). Among AKI patients,
the median time to AKI was 3.6 years (IQR 1.6–5.5 year). Among
these 73 participants, most of them (>80%) had only one
episode of AKI episode during the study period. The median
post-AKI observation period among the 73 participants who ex-
perienced AKI was 2.3 (IQR 0.6–6.0) years.
During the observation period, participants received more
clinical SCr measurements than research Cr measurements
(median 14 clinical versus 8 research; P< 0.001). Among the 73
patients who experienced an episode of AKI, there were also
significantly more clinical SCr measurements (median 10 meas-
urements) than research SCr measurements (median 4 meas-
urements) after each patient’s AKI episode (Table 2).
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Absolute change in outpatient eGFR after AKI
Applying linear mixed effects regression using aggregated data
from both sources of SCr measurements to calculate eGFR val-
ues, we observed a small apparent absolute rise in mean outpa-
tient eGFR level by 2.01 mL/min/1.73 m2 after AKI (Table 3).
There was a statistically significant interaction (P¼ 0.003) be-
tween an episode of AKI and source of SCr with subsequent
acute change in mean outpatient eGFR. In models stratified by
the source of SCr, we observed a small acute rise in mean eGFR
level after AKI when only using clinically obtained SCr (2.20 mL/
min/1.73 m2; P < 0.0001) and a small decrease in mean eGFR
level after AKI when using only research SCr data that were not
statistically significant (0.35 mL/min/1.73 m2; P¼ 0.69; Table 3).
Change in eGFR slope after AKI
Applying linear mixed effects regression using aggregated data
from both sources of SCr measurements, we found the mean
slope of eGFR to be 0.31 mL/min/1.73 m2/year, reflecting a ref-
erent group of patients with mean age 60.3 years, non-black
race, male sex, with ACR <30 mg/g, without diabetes and with-
out having experienced AKI. In other words, this slope reflects
the pre-AKI slope for 73 participants who experienced AKI and
the overall slope for the remainder of the cohort who did not ex-
perience AKI. An episode of AKI was associated with an incre-
mentally faster rate of eGFR decline with an additional faster
rate of decline by 0.67 mL/min/1.73 m2/year (P< 0.0001;
Table 3). In other words, the mean post-AKI slope was
0.31 þ (0.67) ¼0.98 mL/min/1.73 m2/year. There was no sta-
tistically significant interaction between time elapsed after AKI
and source of SCr.
DISCUSSION
In this longitudinal analysis of a unique prospective cohort
of adults with CKD who had repeated SCr measurements, we
found that an episode of AKI was independently associated
with a faster rate of subsequent kidney function decline—by a
mean additional loss of 0.67 mL/min/1.73 m2/year. This degree
of change in eGFR slope is quite modest compared with effect
sizes reported in previous observational studies addressing
changes in kidney function trajectory after AKI. At the same
time, we found that the source of SCr may impact the observed
association of AKI with subsequent absolute change in the next
measured outpatient eGFR level, as clinical data were associ-
ated with a paradoxical small rise in the level of the next ob-
served outpatient eGFR, while research protocol-driven data
were associated with no significant change.
Animal models of AKI have shed light on potential mecha-
nisms of maladaptive repair after AKI, characterized by fibrosis,
vascular rarefaction, tubular loss, glomerulosclerosis and
chronic interstitial inflammation—resulting in a state that
mimics accelerated kidney aging and functional decline [33–36].
Therefore, even modestly steeper eGFR slope after AKI may rep-
resent significant manifestations of accelerated CKD. However,
controversy exists about whether AKI causes or worsens CKD,
owing to the observational nature of prior human studies
and inherent limitations such as the lack of protocol-driven kid-
ney function assessments before and after AKI in clinical prac-
tice and the lack of uniform ascertainment of key confounders
[16, 17, 37].
Our study builds upon the existing body of literature study-
ing AKI as a risk factor for CKD progression, but incorporates
significant methodological strengths to address shortcomings
of prior studies. Importantly, we were able to account for impor-
tant potential confounders in the relationship between AKI and
CKD progression that previous studies were not able to fully
capture, thanks to CRIC’s uniform collection of a complete set of
established risk factors such as preexisting albuminuria, diabe-
tes, lower baseline eGFR and steeper eGFR trajectory prior to
AKI. As noted above, few studies have simultaneously
attempted to control rigorously for pre-AKI proteinuria and pre-
AKI eGFR slope, two key potential confounders often neglected
in prior studies reporting that patients who experienced AKI
had more rapid decline in eGFR than their counterparts who did
not [21]. Our adjustment for these key variables may help to ex-
plain the more modest, independent effect size in the change in
eGFR slope after AKI that we noted, in contrast to prior studies.
For example, in a study analyzing data from US Veterans,
Amdur et al. found that an episode of AKI was associated with a
relative drop in eGFR by >10% both in the immediate 1–3 month
period and the subsequent 3–12 month period after AKI, equiva-
lent to an additional loss of eGFR by as much as approximately
10 mL/min/1.73 m2/year [13]. These estimates without adjust-
ing for albuminuria and slope of eGFR before AKI may overesti-
mate the independent effect of AKI on subsequent kidney
function decline. In a separate study, James et al. used provincial
data from Alberta to study patients undergoing coronary angi-
ography and found that patients who had post-angiography AKI
had a steeper eGFR slope (from 0.8 mL/min/1.73 m2/year after
mild AKI to 2.8 mL/min/1.73 m2/year after more severe AKI)
compared with those without AKI after angiography (0.1 mL/
min/1.73 m2/year) [38]. While the authors of that study modeled
eGFR trajectory in a similar fashion to our current analysis and
attempted to account for proteinuria and baseline rates of kid-
ney function, there was considerable missing data on both pro-
teinuria (22%) and pre-angiography eGFR decline (40%) [38].
In addition, we uniquely addressed the important methodo-
logical question of potential ascertainment bias in previous
reports. As nearly all prior studies [9–12, 38–40] have not used
Table 1. Characteristics of study participants at baseline and during
period of study observation through 13 January 2015
Baseline characteristics n¼ 444
Age, mean (SD), years 60.3 (9.0)
Women, n (%) 297 (66.9)
Black race, n (%) 150 (33.8)
eGFR, mean (SD), mL/min/1.73 m2 51.0 (15.2)
Urine ACR, n (%)
<30 mg/g 269 (60.6)
30 mg/g to 299 mg/g 91 (20.5)
300 mg/g to 999 mg/g 42 (9.5)
1000 mg/g 42 (9.5)
Diabetes mellitus, n (%) 141 (31.8)
Characteristics during period of study observation
Duration of observation, years
Mean (SD) 7.1 (3.3)
Median (IQR) 8.5 (4.4–9.8)
Developed AKI during period of observation, n (%) 73 (16.0)
Stage 1, n (% of all AKI) 40 (54.8)
Stage 2, n (% of all AKI) 17 (23.3)
Stage 3 without dialysis, n (% of all AKI) 12 (16.4)
Stage 3 with dialysis, n (% of all AKI) 4 (5.5)
SD, standard deviation.
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prospectively collected data but instead relied solely on SCr
measurements obtained as a part of routine clinical care, they
were susceptible to bias of more frequent surveillance of kidney
function among patients with AKI [16, 21]. In the present study,
although we observed that patients who had AKI had signifi-
cantly more frequent SCr measurements obtained as a part of
routine clinical care, we found a similar magnitude in rate of ad-
ditional eGFR loss after AKI with no significant interaction with
source of SCr.
In modeling the association of an AKI episode and acute ab-
solute change in outpatient eGFR, we interestingly found a sta-
tistically significant interaction between AKI and source of SCr,
with observed absolute differences that were small but in oppo-
site directions when using only clinical versus only research SCr
measurements (Table 3). This finding may reflect that the ma-
jority of AKI cases in our cohort were mild (55% Stage 1) and
that kidney function may recover back to a baseline eGFR level
by the time the next outpatient measurement is obtained. This
is in contrast to the aforementioned study by Amdur et al., in
which >50% of the cases of AKI defined using administrative
codes met criteria for severe (Stage 3) AKI, and which showed
an crude acute drop in eGFR by 10% post-AKI [13]. The paradoxi-
cal improvement in eGFR following an episode of AKI using clin-
ical measurements only may be because patients hospitalized
with acute illness often develop significant reductions in SCr
concentration at or immediately post discharge, as shown in a
previous study by Prowle et al. [41]. This fall in SCr may be due
to hemodilution from volume resuscitation or acute illness-
associated loss of muscle mass, which leads to decreased creati-
nine generation [41, 42]. These factors may be less important
further out after a hospitalization when the research SCr meas-
urements tended to be done.
We believe that our observation of the modest impact of an
AKI episode on kidney function trajectory after accounting for
potential confounders is novel and important. It helps to recon-
cile the apparent contradiction in the existing literature [16, 17]
on the strength and causality of the AKI–CKD link. While many
observational studies show an association between AKI and
worse kidney function in the subsequent months to years [15],
the few analyses of randomized controlled trials in which the
interventions modestly affected rates of AKI showed no appar-
ent impact on long-term observed kidney function [37, 43]. In
the Coronary Artery Bypass Grafting Surgery Off- or On-pump
Revascularization kidney function sub-study that randomized
2932 patients to ‘off-pump’ versus ‘on-pump’ surgery, Garg et al.
observed that, despite a modest reduction in post-operative AKI
incidence in the group randomized to off-pump surgery, there
was no statistically significant difference in kidney function at 1
year [37]. In that study, however, only 19% of participants expe-
rienced AKI, and >60% of the AKI cases were mild in severity
(i.e. <100% increase in SCr) [37]. Therefore, the observed eGFR
results at 1 year after intervention was determined largely by
individuals who did not experience AKI (81%) plus individuals
who experienced mild AKI (11%). It is likely that the
Table 2. Frequency of serum creatinine testing based on research protocol versus clinical measurements, overall and in the subset of partici-
pants experiencing AKI
Testing during period of observation
Research protocol
obtained measurements
Clinically obtained
measurements P-value
Number of eGFRs observed among entire cohort (n¼ 444)
Mean (SD) 7 (3) 16 (14) <0.0001
Median (IQR) 8 (4–10) 14 (8–22) <0.0001
Number of eGFRs pre-AKI among entire cohorta (n¼444)
Mean (SD) 6 (4) 14(12) <0.0001
Median (IQR) 7 (3–10) 12 (6–18) <0.0001
Number of eGFRs pre-AKI among those experiencing AKI (n¼ 73)
Mean (SD) 4 (2) 9 (8) <0.0001
Median (IQR) 3 (2–6) 8 (3–13) <0.0001
Number of eGFRs post-AKI among those experiencing AKI (n¼ 73)
Mean (SD) 4(3) 16 (19) <0.0001
Median (IQR) 4 (2–6) 10 (5–20) <0.0001
Days between AKI discharge date and first post-AKI eGFR (n¼ 73)
Mean (SD) 128 (70) 107 (286) 0.66
Median (IQR) 119 (68–185) 10 (5–58) 0.01
aIncludes participants who did not experience AKI during observation.
SD, standard deviation.
Table 3. Multivariable mixed effects model showing association of AKI and other predictors on kidney function
Predictors in the model Coefficient (95% CI)
Impact of an AKI episode on acute change in level of eGFRa, ml/min/1.73 m2 2.01 (1.17–2.84)
Impact of an AKI episode on acute change in level of eGFR using only clinical serum creatinine
measurements, ml/min/1.73 m2
2.20 (1.26–3.13)
Impact of an AKI episode on acute change in level of eGFR using only research serum creatinine
measurements, ml/min/1.73 m2
0.35 (2.10 to 1.40)
Impact of an AKI episode on subsequent rate of eGFR declineb, ml/min/1.73 m2/year 0.67 (0.88 to 0.46)
aTest of interaction between AKI and source of serum creatinine P¼ 0.003.
bTest of interaction between time elapsed after AKI and source of serum creatinine P¼0.06.
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combination of only a minority of patients in randomized trials
experiencing AKI, interventions that only modestly changed
AKI rates and the impact of AKI that was mild in severity on
subsequent eGFR being modest (as quantified by our current
study)—helps to reconcile this controversy in the literature.
Our findings may have important practice implications. For
example, providers should be cautious in assigning new base-
line eGFR after an AKI episode, as data from our study and
others [41] suggest the potential for falsely normal or elevated
eGFR in the early post-hospitalization period after AKI when re-
lying on clinical SCr measurements. Healthy People 2020 lists as
one of its goals to increase the proportion of AKI survivors who
have follow-up renal function evaluation within 6 months post-
discharge [44], a practice also promoted by the 2012 KDIGO
Clinical Practice Guidelines for AKI [25] and the AKI Advisory
Group of the American Society of Nephrology [45]. If the impact
of mild AKI on subsequent kidney function decline is quite
modest, it would seem prudent to prioritize early nephrology in-
volvement during the post-AKI course for higher risk individu-
als, such as those with preexisting CKD and those who survived
more severe forms of AKI [46] rather than instituting blanket
post-AKI care components for everyone.
Our study has some limitations. Our approach may exclude
some patients with community-acquired AKI, who are admitted
with SCr values that were higher than their steady state pread-
mission baseline value and who do not recover sufficiently dur-
ing hospitalizations to meet the [peak/nadir SCr] ratio threshold
we used to define AKI. However, in those cases, it may be diffi-
cult to distinguish whether a person truly had AKI or just rela-
tively rapid progression of underlying CKD since both those
scenarios can give the observed SCr patterns. Validated urine
output data were not available [28]. We also lacked more granu-
lar data from hospitalizations to characterize potential causes
of AKI, as different etiologies (e.g. acute tubular necrosis vs pre-
renal azotemia) may produce different estimates on the impact
of AKI on CKD progression. Our sample size was not large.
However, our confidence intervals indicate that we estimated
effect sizes with reasonable precision. The predominantly
milder AKI episodes and modest absolute number of AKI epi-
sode meant that our results cannot be fully extrapolated to se-
vere AKI (e.g. dialysis-requiring AKI) in which the data are much
stronger that it substantially accelerates kidney function loss [9,
10]. The time gap between episodes of AKI and measurement of
outpatient eGFR (both before and after) was not controlled but
this should not introduce substantial biases as the mixed effect
models takes into account information from all study partici-
pants (both those with and those without AKI) to model individ-
ual (as well as group level) eGFR trajectories and can handle
well variations in spacing of eGFR readings. The model does as-
sume that kidney function uniformly declines in a linear fash-
ion over time [47, 48]. Within the time frame of our study and
frequency of outpatient eGFR measurements, this is not an un-
reasonable assumption [49, 50] and one would expect any devia-
tion to affect both those who did and did not experience AKI.
In conclusion, AKI appears to be independently associated
with accelerated subsequent kidney function decline, but the
adjusted effect size was much smaller than previously reported
after accounting for potential confounders, including pre-AKI
proteinuria and eGFR slope. The source of SCr measurements
before and after an episode of AKI used to estimate kidney func-
tion may influence the observed association with AKI depend-
ing on the outcome studied. Larger studies using longitudinal
data from protocol-driven, more frequent measurements of SCr,
or from alternative filtration markers that may be less impacted
by acute illness such as serum cystatin C [51], are needed to
clarify the link between AKI and subsequent kidney function
loss. In addition, uniform ascertainment and adjustment for
pre-AKI factors such as proteinuria and eGFR slope are para-
mount toward minimizing residual confounding in elucidating
this association.
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